| Literature DB >> 31243306 |
Jody E Phelan1, Dodge R Lim2,3, Satoshi Mitarai4, Paola Florez de Sessions5, Ma Angelica A Tujan6, Lorenzo T Reyes2,3, Inez Andrea P Medado6, Alma G Palparan2,3, Ahmad Nazri Mohamed Naim5, Song Jie5, Edelwisa Segubre-Mercado6, Beatriz Simoes1, Susana Campino1, Julius C Hafalla1, Yoshiro Murase4, Yuta Morishige4, Martin L Hibberd1, Seiya Kato4, Ma Cecilia G Ama2,3, Taane G Clark7,8.
Abstract
The Philippines has a high incidence of tuberculosis disease (TB), with an increasing prevalence of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) strains making its control difficult. Although the M. tuberculosis "Manila" ancient lineage 1 strain-type is thought to be prevalent in the country, with evidence of export to others, little is known about the genetic diversity of circulating strains. By whole genome sequencing (WGS) 178 isolates from the Philippines National Drug Resistance Survey, we found the majority (143/178; 80.3%) belonged to the lineage 1 Manila clade, with the minority belonging to lineages 4 (European-American; n = 33) and 2 (East Asian; n = 2). A high proportion were found to be multidrug-resistant (34/178; 19.1%), established through highly concordant laboratory drug susceptibility testing and in silico prediction methods. Some MDR-TB isolates had near identical genomic variation, providing potential evidence of transmission. By placing the Philippine isolates within a phylogeny of global M. tuberculosis (n > 17,000), we established that they are genetically similar to those observed outside the country, including a clade of Manila-like strain-types in Thailand. An analysis of the phylogeny revealed a set of ~200 SNPs that are specific for the Manila strain-type, and a subset can be used within a molecular barcode. Sixty-eight mutations known to be associated with 10 anti-TB drug resistance were identified in the Philippine strains, and all have been observed in other populations. Whilst nine putative streptomycin resistance conferring markers in gid (8) and rrs (1) genes appear to be novel and with functional consequences. Overall, this study provides an important baseline characterisation of M. tuberculosis genetic diversity for the Philippines, and will fill a gap in global datasets and aid the development of a nation-wide database for epidemiological studies and clinical decision making. Further, by establishing a molecular barcode for detecting Manila strains it will assist with the design of diagnostic tools for disease control activities.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31243306 PMCID: PMC6594935 DOI: 10.1038/s41598-019-45566-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The 178 M. tuberculosis isolates: (A) Map of the Philippines annotated with the source and drug-resistance of the isolates; (B) A phylogenetic tree constructed using 17,522 SNPs.
Mycobacterium tuberculosis samples (N = 178).
| Characteristic | N | % |
|---|---|---|
|
| ||
| Luzon | 105 | 59.0 |
| Visayas | 37 | 20.8 |
| Mindanao | 36 | 20.2 |
|
| ||
| | 143 |
|
| | 2 |
|
| | 33 |
|
|
| ||
| Rifampicin | 38 |
|
| Isoniazid | 64 |
|
| Ethambutol | 10 |
|
| Streptomycin | 25 |
|
| Amikacin | 2 |
|
| Capreomycin | 2 |
|
| Kanamycin | 8 |
|
| Pan-susceptible | 97 |
|
| MDR-TB | 34 |
|
| XDR-TB | 0 |
|
*Island of collection for sequenced isolates.
**The number resistant to the drug and percentage of tested isolates resistant; the denominator is the number of isolates for each drug with successfully performed susceptibility tests. The exception to this is the proportion of pan-susceptible which was calculated using the total number of samples.
MDR-TB = multi-drug resistant; XDR-TB = extensively-drug resistant; there was no levofloxacin drug resistance.
Drug resistance mutations with frequency greater than one.
| Drug | Gene | Mutation | Freq. (%) | Global freq* (%) |
|---|---|---|---|---|
| Isoniazid |
| S315T | 63 | 4057/5423 (74.8) |
| Rifampicin |
| S450L | 37 | 2968/4618 (64.3) |
| Isoniazid/Ethionamide |
| C-15T | 35 | 872/5423 (16.1) |
| Ethambutol |
| M306I | 15 | 564/2662 (21.2) |
| Streptomycin |
| A514C | 11 | 128/1408 (9.1) |
| Streptomycin |
| K88R | 7 | 103/1408 (7.3) |
| Rifampicin |
| H445Y | 6 | 230/4618 (5.0) |
| Isoniazid |
| I21V | 5 | 15/5423 (0.3) |
| Ethambutol |
| M306V | 4 | 839/2662 (31.5) |
| Isoniazid/Ethionamide |
| T-8C | 4 | 89/5423 (1.6) |
| Ethambutol |
| Q497K | 3 | 20/2662 (0.8) |
| Isoniazid/Ethionamide |
| G-17T | 3 | 72/5423 (1.3) |
| Isoniazid/Ethionamide |
| I21T | 3 | 32/5423 (0.6) |
| Streptomycin |
| 102del | 3 | 12/1408 (0.9) |
| Streptomycin |
| 351del | 3 | 6/1408 (0.4) |
| Streptomycin |
| K43R | 3 | 642/1408 (45.6) |
| Ethambutol |
| D4N | 2 | 3/2662 (0.1) |
| Ethambutol |
| D328G | 2 | 16/2662 (0.6) |
| Ethambutol |
| G406D | 2 | 75/2662 (2.8) |
| Isoniazid/Ethionamide |
| I194T | 2 | 88/5423 (1.6) |
| Pyrazinamide |
| D12A | 2 | 11/1946 (0.6) |
| Pyrazinamide |
| G24D | 2 | 3/1946 (0.2) |
| Pyrazinamide |
| I133T | 2 | 24/1946 (1.2) |
| Rifampicin |
| 1297_1298insTTC | 2 | 11/4618 (0.2) |
| Rifampicin |
| 1295_1303del | 2 | 5/4618 (0.1) |
| Rifampicin |
| D435F | 2 | 23/4618 (0.5) |
| Rifampicin |
| S441L | 2 | 17/4618 (0.4) |
| Streptomycin |
| 386del | 2 | 2/1408 (0.1) |
| Streptomycin |
| C517T | 2 | 57/1408 (4.1) |
*Based on the 17k dataset.